摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-Amino-6-chloro-5-nitro-2-[(phenylmethyl)thio]pyrimidine | 354582-78-8

中文名称
——
中文别名
——
英文名称
4-Amino-6-chloro-5-nitro-2-[(phenylmethyl)thio]pyrimidine
英文别名
6-chloro-5-nitro-2-[(phenylmethyl)thio]-4-pyrimidinamine;2-(Benzylthio)-6-chloro-5-nitropyrimidin-4-amine;2-benzylsulfanyl-6-chloro-5-nitropyrimidin-4-amine
4-Amino-6-chloro-5-nitro-2-[(phenylmethyl)thio]pyrimidine化学式
CAS
354582-78-8
化学式
C11H9ClN4O2S
mdl
——
分子量
296.737
InChiKey
TWTMMICMISMLKM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    515.9±50.0 °C(Predicted)
  • 密度:
    1.54±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    19
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    123
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Evaluation of a series of bicyclic CXCR2 antagonists
    摘要:
    The CXCR2 SAR of a series of bicyclic antagonists such as the 2-aminothiazolo[4,5-d]pyrimidine 3b was investigated by systematic variation of the fused pyrimidine-based heterocyclic cores. Replacement of the aminothiazole ring with a 2-thiazolone alternative led to a series of thiazolo[4,5-d]pyrimidine-2(3H)-one antagonists with markedly improved biological and pharmacokinetic properties, which are suitable pharmacological tools to probe the in vivo effects of CXCR2 antagonism combined with the associated CCR2 activity. (c) 2007 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2007.11.039
  • 作为产物:
    描述:
    4,6-Dichloro-5-nitro-2-[(phenylmethyl)thio]-pyrimidineN,N-二异丙基乙胺 作用下, 以 1,4-二氧六环 为溶剂, 以52%的产率得到4-Amino-6-chloro-5-nitro-2-[(phenylmethyl)thio]pyrimidine
    参考文献:
    名称:
    Evaluation of a series of bicyclic CXCR2 antagonists
    摘要:
    The CXCR2 SAR of a series of bicyclic antagonists such as the 2-aminothiazolo[4,5-d]pyrimidine 3b was investigated by systematic variation of the fused pyrimidine-based heterocyclic cores. Replacement of the aminothiazole ring with a 2-thiazolone alternative led to a series of thiazolo[4,5-d]pyrimidine-2(3H)-one antagonists with markedly improved biological and pharmacokinetic properties, which are suitable pharmacological tools to probe the in vivo effects of CXCR2 antagonism combined with the associated CCR2 activity. (c) 2007 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2007.11.039
点击查看最新优质反应信息

文献信息

  • Pyrimidine compounds and their use as modulators of chemokine receptor activity
    申请人:——
    公开号:US20030040523A1
    公开(公告)日:2003-02-27
    The invention provides certain heterocyclic compounds, processes, and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy; in formula (I), A is a group of formula (a) or (b).
    这项发明提供了某些杂环化合物,其制备过程和中间体,包含它们的药物组合物以及它们在治疗中的应用;在式(I)中,A是式(a)或(b)的基团。
  • PYRIMIDINE COMPOUNDS AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
    申请人:AstraZeneca AB
    公开号:EP1257555B1
    公开(公告)日:2003-12-03
  • US6958344B2
    申请人:——
    公开号:US6958344B2
    公开(公告)日:2005-10-25
  • [EN] PYRIMIDINE COMPOUNDS AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY<br/>[FR] COMPOSES PYRIMIDINIQUES ET LEUR UTILISATION COMME MODULATEURS DE L'ACTIVITE DES RECEPTEURS DE CHIMIOKINE
    申请人:ASTRAZENECA AB
    公开号:WO2001058906A1
    公开(公告)日:2001-08-16
    The invention provides certain pyrimidine compounds, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy. Formula (I) in which: A is a group of formula (a), (b) or (c).
  • [EN] PYRIMIDINE COMPOUNDS AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY<br/>[FR] COMPOSES DE PYRIMIDE ET LEUR UTILISATION COMME MODULATEURS DE L'ACTIVITE DU RECEPTEUR DE CHIMIOKINE
    申请人:ASTRAZENECA AB
    公开号:WO2001058902A1
    公开(公告)日:2001-08-16
    The invention provides certain heterocyclic compounds, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy; in formula (I), A is a group of formula (a) or (b).
查看更多